ZENOTECH LABORATORIES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 62.4 INR | 0.00% |
|
-0.57% | -6.28% |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,484 | 1,297 | 897.1 | 2,136 | 3,073 | 2,872 |
| Enterprise Value (EV) 1 | 2,277 | 1,367 | 1,073 | 2,318 | 3,109 | 2,761 |
| P/E ratio | -18.2 x | -41.5 x | 8.32 x | -175 x | 13.9 x | 24.8 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 22.3 x | 9.95 x | 3.46 x | 11 x | 9.33 x | 7.36 x |
| EV / Revenue | 20.4 x | 10.5 x | 4.14 x | 12 x | 9.44 x | 7.08 x |
| EV / EBITDA | -29.1 x | -42 x | 11.9 x | 36.3 x | 17.4 x | 12.9 x |
| EV / FCF | -7.97 x | -4.86 x | -4.92 x | -148 x | 26.6 x | 26 x |
| FCF Yield | -12.5% | -20.6% | -20.3% | -0.68% | 3.75% | 3.84% |
| Price to Book | 5.91 x | 3.33 x | 1.81 x | 4.41 x | 4.35 x | 3.49 x |
| Nbr of stocks (in thousands) | 61,031 | 61,031 | 61,031 | 61,031 | 61,031 | 61,031 |
| Reference price 2 | 40.70 | 21.25 | 14.70 | 35.00 | 50.35 | 47.06 |
| Announcement Date | 06/09/18 | 27/08/19 | 02/09/20 | 02/09/21 | 30/08/22 | 05/09/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 111.4 | 130.3 | 259.4 | 193.7 | 329.5 | 390.1 |
| EBITDA 1 | -78.16 | -32.59 | 89.8 | 63.8 | 179.2 | 213.6 |
| EBIT 1 | -117.2 | -74.61 | 41.3 | -0.76 | 109.4 | 141.9 |
| Operating Margin | -105.16% | -57.27% | 15.92% | -0.39% | 33.21% | 36.37% |
| Earnings before Tax (EBT) 1 | -118.5 | -31.27 | 107.8 | -12.15 | 99.01 | 145 |
| Net income 1 | -118.5 | -31.27 | 107.8 | -12.15 | 221.8 | 115.9 |
| Net margin | -106.34% | -24% | 41.55% | -6.27% | 67.31% | 29.7% |
| EPS 2 | -2.240 | -0.5124 | 1.766 | -0.2000 | 3.630 | 1.898 |
| Free Cash Flow 1 | -285.6 | -281.4 | -218.3 | -15.66 | 116.7 | 106.1 |
| FCF margin | -256.25% | -215.95% | -84.16% | -8.08% | 35.43% | 27.19% |
| FCF Conversion (EBITDA) | - | - | - | - | 65.15% | 49.66% |
| FCF Conversion (Net income) | - | - | - | - | 52.64% | 91.56% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 06/09/18 | 27/08/19 | 02/09/20 | 02/09/21 | 30/08/22 | 05/09/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 70.4 | 176 | 182 | 35.9 | - |
| Net Cash position 1 | 207 | - | - | - | - | 111 |
| Leverage (Debt/EBITDA) | - | -2.161 x | 1.957 x | 2.852 x | 0.2001 x | - |
| Free Cash Flow 1 | -286 | -281 | -218 | -15.7 | 117 | 106 |
| ROE (net income / shareholders' equity) | 99.2% | -7.73% | 24.3% | -2.48% | 37.3% | 15.2% |
| ROA (Net income/ Total Assets) | -11.1% | -5.61% | 3.03% | -0.06% | 7.6% | 9.1% |
| Assets 1 | 1,072 | 557.7 | 3,552 | 21,933 | 2,917 | 1,274 |
| Book Value Per Share 2 | 6.880 | 6.370 | 8.130 | 7.930 | 11.60 | 13.50 |
| Cash Flow per Share 2 | 4.650 | 2.160 | 0.1800 | 0.4000 | 0.4000 | 1.830 |
| Capex 1 | 38.2 | 180 | 217 | 49.1 | 19.4 | 62.3 |
| Capex / Sales | 34.32% | 138.41% | 83.84% | 25.35% | 5.88% | 15.97% |
| Announcement Date | 06/09/18 | 27/08/19 | 02/09/20 | 02/09/21 | 30/08/22 | 05/09/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -6.28% | 4.56Cr | |
| +31.83% | 59TCr | |
| -3.42% | 36TCr | |
| +18.02% | 33TCr | |
| +4.27% | 29TCr | |
| +15.26% | 24TCr | |
| +9.92% | 21TCr | |
| -7.16% | 20TCr | |
| +8.12% | 17TCr | |
| -1.42% | 16TCr |
- Stock Market
- Equities
- ZENOTECH6 Stock
- Financials Zenotech Laboratories Limited